- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
State of the Industry 2006
Summarizing the Healthcare industry and the state of the precarious union between providers and payers is like trying to balance a gallon of fresh gelatin in your hands. Every time you think you've got it all together, it begins to slip to one side or right through your fingers. Healthcare is an industry perhaps more complex, fragmented and difficult to comprehend than any other. When we try to understand the dynamics that make our industry such a challenge in which to work, we inevitably underestimate the impact of one force or overlook a series of other competing agendas altogether. It's a slippery slope to think we can understand it all, let alone control it.
Welcome to MANAGED HEALTHCARE EXECUTIVE's State of the Industry Report. We hope to make sense of the various "balancing acts" in our industry and to prepare you for another challenging year.
Act 1: Capital Ideas. The State of the Industry Report monitors a market basket of metrics that in this particular year, demonstrate a leveling off of many economic indicators. Spending on healthcare services for privately insured individuals, for example, increased 8.2% in 2004, according to the Center for Studying Health System Change, virtually the same rate of increase measured the year before. However, this rate continues to outpace the growth of the economy overall, which increased a respectable 5.6% during the same period. According to the Center, continued or growing gaps between these measures will make health insurance increasingly more difficult to obtain and maintain for certain segments of the market.
If the health system CEO feels guarded optimism from the stabilization of industry benchmarks, the managed care CEO is likely basking in reports that this segment continues to be strong. Indeed, while half of the rated nonprofit health systems were downgraded versus upgraded, half of the nation's HMOs are considered "financially strong," according to Weiss Ratings Inc., an independent provider of ratings for service and financial sectors. Based on data from the second quarter of 2004, the percentage of insurers receiving a Weiss rating of A (excellent) or B (good) rose to 50%, a significant increase from 1998, when only 20.8% of HMOs qualified. Of the 482 HMOs reviewed by Weiss during 2004, 65 companies were upgraded, while only three were downgraded.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
